These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257 [TBL] [Abstract][Full Text] [Related]
48. Decreased dopamine D receptor binding in essential blepharospasm. Horie C; Suzuki Y; Kiyosawa M; Mochizuki M; Wakakura M; Oda K; Ishiwata K; Ishii K Acta Neurol Scand; 2009 Jan; 119(1):49-54. PubMed ID: 18540899 [TBL] [Abstract][Full Text] [Related]
49. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219 [TBL] [Abstract][Full Text] [Related]
50. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride. Vollenweider FX; Vontobel P; Hell D; Leenders KL Neuropsychopharmacology; 1999 May; 20(5):424-33. PubMed ID: 10192823 [TBL] [Abstract][Full Text] [Related]
51. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116 [TBL] [Abstract][Full Text] [Related]
52. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Drevets WC; Price JC; Kupfer DJ; Kinahan PE; Lopresti B; Holt D; Mathis C Neuropsychopharmacology; 1999 Dec; 21(6):694-709. PubMed ID: 10633475 [TBL] [Abstract][Full Text] [Related]
53. Long-term test-retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [(11)C]raclopride and high-resolution PET. Alakurtti K; Johansson JJ; Joutsa J; Laine M; Bäckman L; Nyberg L; Rinne JO J Cereb Blood Flow Metab; 2015 Jul; 35(7):1199-205. PubMed ID: 25853904 [TBL] [Abstract][Full Text] [Related]
54. Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain. Ginovart N; Farde L; Halldin C; Swahn CG Synapse; 1997 Apr; 25(4):321-5. PubMed ID: 9097390 [TBL] [Abstract][Full Text] [Related]
55. PET studies of the effects of aerobic exercise on human striatal dopamine release. Wang GJ; Volkow ND; Fowler JS; Franceschi D; Logan J; Pappas NR; Wong CT; Netusil N J Nucl Med; 2000 Aug; 41(8):1352-6. PubMed ID: 10945526 [TBL] [Abstract][Full Text] [Related]
56. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Batool F; Hasnat A; Haleem MA; Haleem DJ Acta Pharm; 2010 Jun; 60(2):129-40. PubMed ID: 21134850 [TBL] [Abstract][Full Text] [Related]
57. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. te Beek ET; de Boer P; Moerland M; Schmidt ME; Hoetjes NJ; Windhorst AD; van Berckel BN; Cohen AF; van Gerven JM; Lammertsma AA J Psychopharmacol; 2012 Aug; 26(8):1128-35. PubMed ID: 22290934 [TBL] [Abstract][Full Text] [Related]
58. Dopamine and serotonin interactions in the modulation of the expression of the immediate-early transcription factor, nerve growth factor-inducible B, in the striatum. Gervais J; Soghomonian JJ; Richard D; Rouillard C Neuroscience; 1999; 91(3):1045-54. PubMed ID: 10391482 [TBL] [Abstract][Full Text] [Related]
59. A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system. Volonté MA; Moresco RM; Gobbo C; Messa C; Carpinelli A; Rizzo G; Comi G; Fazio F Neurol Sci; 2001 Feb; 22(1):107-8. PubMed ID: 11487182 [TBL] [Abstract][Full Text] [Related]
60. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]